Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product
you will need to google the titles above & belowPositive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
########
16,000 people in USA suffer from CIDP - this is nowhere near 25% of Ig use & the article mentions some CIDP patients use Ig & some use corticosteroids & now Argenx Vyvgart looks like a successful treatment preventing relapse in over 60% of patients - so it's not the magic cure but a very effective treatment & extra option along with Ig & Corticosteroids
Argenx looks to be doing incredible work & will likely attract takeover interest from larger biotech companies - the enzyme based drug delivery system also looks very promising
If Argenx continues to develop targeted therapies it is good for patients & will provide insight into more potential refined or expanded uses of CSL Ig products if deemed worth investigating & modifying
Vyvgart shines in CIDP study, teeing up another potential nod...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.00 |
Change
2.260(0.78%) |
Mkt cap ! $141.5B | |||
| Open | High | Low | Value | Volume |
| $294.00 | $294.75 | $290.82 | $491.6M | 1.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8192 | $292.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.06 | 12368 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |